Checking MRD after surgery in early lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at a test called MRD (tiny remaining cancer after treatment) after surgery for early-stage lung cancer. It aims to understand who is more likely to have the cancer return, which could help guide follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage (Stage I–II) lung cancer that can be removed by surgery
- You’re age 18 or older
- Your lung cancer diagnosis is confirmed as non-small cell lung cancer (NSCLC)
- You have not had any prior cancer treatment (no surgery, chemo, radiation, targeted therapy, or immunotherapy)
- Your health is good enough for surgery and follow-up treatments (ECOG performance status 0–1)
- You can attend study visits and tests, and you expect to live at least 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a special blood/tissue test called MRD (minimal residual disease, meaning tiny leftover cancer signals) can help monitor lung cancer after surgery. It may help doctors spot relapse earlier after your tumor has been fully removed.
This study checks if people with early-stage non-small cell lung cancer can safely skip chemotherapy or radiation after surgery when repeated blood tests show no sign of cancer left. You would only be watched with regular scans and blood tests to make sure the cancer doesn't come back.
This trial is studying a blood test that looks for tiny bits of cancer DNA after surgery for stage III colorectal cancer. The goal is to find out how well this test can predict whether cancer might come back, so you and your doctor can make better treatment decisions.
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
Hear when a new NSCLC MRD ctDNA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.